Oxybutynin
OXYTROL
Cholinergic Muscarinic Antagonist
NADAC/unit
$0.0324
No Shortage
Tier 1: 155.9%
PA Req: 3.0%
21 Manufacturers
39 ANDAs
Oxybutynin chloride extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
vs. brand OXYTROL: Generic saves up to 100% per unit
Active Shortages
2025-05-14 Shortage reported, Upsher-Smith Laboratories, LLC
2025-05-14 Shortage reported, Upsher-Smith Laboratories, LLC
2025-05-14 Shortage reported, Upsher-Smith Laboratories, LLC
2025-05-14 Shortage reported, Upsher-Smith Laboratories, LLC
Market Intelligence
2023-11-15 Class II Recall: Zydus Pharmaceuticals (USA) Inc
2023-11-15 Class II Recall: Zydus Pharmaceuticals (USA) Inc
2023-11-15 Class II Recall: Zydus Pharmaceuticals (USA) Inc
2023-10-11 Class II Recall: Zydus Pharmaceuticals (USA) Inc
Generic Manufacturers
ABHAI LLCACCORD HEALTHCARE INCAIPING PHARMACEUTICAL INCAJANTA PHARMA LTDALLERGAN SALES LLCAMNEAL PHARMACEUTICALSBIONPHARMA INCCHARTWELL RX SCIENCES LLCLANNETT CO INCLEADING PHARMA LLCNOVAST LABORATORIES LTDNOVITIUM PHARMA LLCOSMOTICA PHARMACEUTICAL US LLCREGCON HOLDINGS LLCRISING PHARMA HOLDINGS INCRUBICON RESEARCH LTDSTRIDES PHARMA GLOBAL PTE LTDSTRIDES PHARMA INTERNATIONAL AGTEVA PHARMACEUTICALS USA INCTP ANDA HOLDINGS LLCUNIQUE PHARMACEUTICAL LABORATORIES A DIV OF JB CHEMICALS AND PHARMACEUTICALS LTDZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.